Coronavirus

No evidence of an association between genetically predicted vitamin D levels and COVID-19 susceptibility were found in the study.

Analysis of medications used in California hospitals over the course of 2020 highlights “evidence-based decisions.”

Younger participants in the study had a higher percentage of stokes than seen in the general population.

Hamsters treated with the therapy did not lose any bodyweight and had reduced virus particles in their lungs.

Worries mount in Africa as only 2% of the population has received a vaccine.

Do the very freedoms Americans enjoy allow us to make less than optimal choices? And will it prevent us from doing what medical science says is best if needed again?

New research from Emory show a significant difference in institutional antibiotic prescribing after education on the value of PCT testing in infected patients last year.

Rates of acute myocardial infarction were higher in those with genetic risks for familial hypercholesterolemia.

The newest data for the real-world assessment show the mRNA vaccine provides greater immunogenicity in persons aged 12-15 years old than in young adults.

Patients with hypoxemia or tachypnea had an overall greater mortality risk compared to those without them.

Participants with a prior case of disease showed cells in their bone marrow up to 4 months after their initial infection.

Sotrovimab was developed by GlaxoSmithKline and Vir Biotechnology to treat mild-to-moderate disease in adults and pediatric patients.

Reports of myocarditis were reported in mostly young adult males, 4 days after administration.

Lower levels of testosterone in the blood were also associated with increased inflammation.

Nearly half of COVID-19 patients never received rehabilitation evaluation and 20% lost daily living abilities.

Early treatment with lenzilumab improved the likelihood of survival without ventilation by 54% among patients hospitalized with COVID-19 who were hypoxic but not on invasive mechanical ventilation, a new study found.

The guidelines were welcomed by some, but infectious disease providers say caution is needed moving forward.

India pushes 300,000 COVID-19 death mark as worries of black fungus loom.

The company plans to file for Food and Drug Administration (FDA) authorization for the 12-17 year old population in early June.

Routine screening of employees at St. Jude Children’s Research Hospital show lower rates of asymptomatic SARS-CoV-2 infection among vaccinated workers.

There is still much to understand in the cases for those who did not require hospitalization but have lingering symptoms that can cause quality-of-life issues.

An investigational therapy demonstrated neutralizing antibodies as well as protection against the virus in preclinical trials.

A diagnostic analyzer was studied looking at 3 biomarkers to predict the level of COVID-19, and could potentially serve as a risk stratification tool.

A majority of the study participants experienced symptoms that interfered with activities of their daily life.

The IL-6 targeting monoclonal antibody is linked to improved inflammatory and hemodynamic markers in hospitalized patients.

A concerted effort to increase flu vaccination during the COVID-19 pandemic resulted in more protection among a high-risk population, as well as educational opportunities for pharmacy students.

The federal agency elongates the time from 5 days up to 1 month for thawed out doses of the Pfizer-BioNTech vaccine.

Kits created by companies like Cepheid and bioMérieux will aid in the testing and treatment of viral infections in the future.

Children who experienced MIS-C showed an elevation of certain adaptive immune responses that confer immunological memory.

Patients who received the therapy had half the rate of mortality at 28 days after treatment.